An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections

The role of host genetic factors in conferring predisposition or protection in infectious diseases has become evident. Infection with group A streptococci causes a wide spectrum of disease ranging from pharyngitis to streptococcal toxic shock syndrome. The release of inflammatory cytokines triggered by streptococcal superantigens has a pivotal role in invasive streptococcal disease. However, individuals infected with the same strain can develop very different manifestations. We report here that the immunogenetics of the host influence the outcome of invasive streptococcal infection, and demonstrate the underlying mechanism for these genetic associations. Specific human leukocyte antigen class II haplotypes conferred strong protection from severe systemic disease, whereas others increased the risk of severe disease. Patients with the DRB1*1501/DQB1*0602 haplotype mounted significantly reduced responses and were less likely to develop severe systemic disease (P < 0.0001). We propose that human leukocyte antigen class II allelic variation contributes to differences in severity of invasive streptococcal infections through their ability to regulate cytokine responses triggered by streptococcal superantigens.

[1]  P. Linsley,et al.  CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses. , 1995, Journal of immunology.

[2]  O. Olerup,et al.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. , 1992, Tissue antigens.

[3]  L. Burman,et al.  Outbreak of group A streptococcal bacteremia in Sweden: an epidemiologic and clinical study. , 1991, The Journal of infectious diseases.

[4]  R. Kaul,et al.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Kaul,et al.  Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. , 1997, The American journal of medicine.

[6]  K. Lundin,et al.  Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity. , 1996, Journal of immunology.

[7]  Malak Kotb,et al.  Genetic Relatedness and Superantigen Expression in Group A Streptococcus Serotype M1 Isolates from Patients with Severe and Nonsevere Invasive Diseases , 2000, Infection and Immunity.

[8]  A. Norrby-Teglund,et al.  Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection , 2000, European journal of immunology.

[9]  B. Schwartz,et al.  Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. , 1999, Infection and immunity.

[10]  A. Norrby-Teglund,et al.  Differential induction of Th1 versus Th2 cytokines by group A streptococcal toxic shock syndrome isolates , 1997, Infection and immunity.

[11]  R. Kaul,et al.  Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndrome—A Comparative Observational Study , 1999 .

[12]  B. Schwartz,et al.  The Reemergence of Severe Group A Streptococcal Disease: an Evolutionary Perspective , 1998 .

[13]  J. Blackwell,et al.  Genetics and genomics in infectious disease susceptibility. , 2001, Trends in molecular medicine.

[14]  G. Thomson,et al.  HLA class II associations with rheumatic heart disease are more evident and consistent among clinically homogeneous patients. , 1999, Circulation.

[15]  J. Ho An epidemiologic and clinical study of nasopharyngeal carcinoma. , 1978, International journal of radiation oncology, biology, physics.

[16]  M. Kotb,et al.  Bacterial pyrogenic exotoxins as superantigens , 1995, Clinical microbiology reviews.

[17]  P. Marrack,et al.  HLA-DR alleles differ in their ability to present staphylococcal enterotoxins to T cells , 1990, The Journal of experimental medicine.

[18]  Martin Pr,et al.  Streptococcal Serogroup: A Epidemic in Norway 1987–1988 , 1990 .

[19]  B. Schwartz,et al.  The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. , 1993, JAMA.

[20]  B. Schwartz,et al.  Selective Depletion Of Vβ-Bearing T Cells In Patients With Severe Invasive Group A Streptococcal Infections And Streptococcal Toxic Shock Syndrome , 1995 .

[21]  D E Low,et al.  Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. , 1996, The New England journal of medicine.

[22]  A. Efstratiou,et al.  The serotypes of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease. , 1993, Journal of medical microbiology.

[23]  A. Norrby-Teglund,et al.  Evidence for superantigen involvement in severe group a streptococcal tissue infections. , 2001, The Journal of infectious diseases.

[24]  S. Dye,et al.  An evolutionary perspective of the knee. , 1987, The Journal of bone and joint surgery. American volume.